Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


PB-GG-OCT4-1-5-PGK-Puro Citations (1)

Originally described in: Human pluripotent reprogramming with CRISPR activators.
Weltner J, Balboa D, Katayama S, Bespalov M, Krjutskov K, Jouhilahti EM, Trokovic R, Kere J, Otonkoski T Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
PubMed Journal

Articles Citing PB-GG-OCT4-1-5-PGK-Puro

Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma. Routila J, Qiao X, Weltner J, Rantala JK, Carpen T, Hagstrom J, Makitie A, Leivo I, Ruuskanen M, Soderlund J, Rintala M, Hietanen S, Irjala H, Minn H, Westermarck J, Ventela S. Oral Oncol. 2022 Apr;127:105772. doi: 10.1016/j.oraloncology.2022.105772. Epub 2022 Mar 1. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.